Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

NCT02582827 is registered in ClinicalTrials.gov with NantBioScience, Inc. as lead sponsor.

NCT NCT02582827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02582827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
Lead sponsor
NantBioScience, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
November 13, 2017
Completion date
August 23, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplastic disease